By Kate Barker, Communications Coordinator
On Friday, October 8 and Saturday, October 9, 2010 in New York City, the National Comprehensive Cancer Network (NCCN) hosted its 5th Annual Congress: Hematologic Malignancies™. Nearly 700 people attended the two-day session to watch expert clinicians from NCCN Member Institutions present on a variety of topics related to the complex nature and treatment of hematologic malignancies.
The first session, plasma cell neoplasms, focused on the diagnosis and management of Myeloma and Waldenström Macrogloblinemia. Experts discussed evolving treatment strategies as well as the optimization of bone health in patients with myeloma.
Next, NCCN clinicians explored developing treatment strategies in Chronic Myelogenous Leukemia. This was followed by a discussion of emerging treatments in lymphomas, specifically in Adult T-Cell Leukemia and Hodgkin Lymphoma. Friday’s robust agenda concluded with a presentation on Hepatitis B viral reactivation in patients with hematologic malignancies.
Saturday’s schedule was similarly diverse and informative. The day commenced with a session on practice issues in hematologic oncology and the role of informatics tools for guiding therapy in hematologic malignancies. Next, discussion centered on supportive care and new directions in the prevention and management of venous thromboembolism. Building upon this supportive care focus was the following presentation on the prevention of infection in patients with hematologic malignancies. NCCN physicians then addressed myeloid growth factors for the management of febrile neutropenia. The Congress concluded with an exploration of the management of disease-specific complications in Chronic Lymphocytic Leukemia.This range of timely and important presentations in conjunction with the technologies, products, and programs showcased by exhibitors provided attendees with a rich and educational experience. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances, and the NCCN 5th Annual Congress: Hematologic Malignancies™ once again proved an effective and innovative forum for doing so.